Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196), was established in 1994 and listed on Shanghai Stock Exchange in August 1998. Now it has turned a leading listed company in Chinese pharmaceutical industry.

Fosun Pharma’s net profits have increased by 13.55 times since its 13-year listed and its annual compound growth rate has reached 24.26%. Meanwhile, its net assets and net profits are in front rank of the listed companies in Chinese pharmaceutical industry.

Fosun Pharma specializing in modern biological medical & health industry, has taken great opportunities of the rapid growth of China’s medical market and Chinese enterprises’ access to the world’s predominant medical market, and accelerated industry integration and implemented key product strategy by following the business principle of “Brand, Innovation, High-efficiency and Globalization” so as to realize stable operation and rapid development, at the same time, it has become a large pharmaceutical group on the aspect of R&D, innovation, marketing, merging & integration and team building by regarding R&D, manufacturing and distribution of the medicines as the core and taking the lead of the scale and market role in diagnostic medicines and medical instruments.

Fosun Pharma has attached great importance to innovation and development and possesses state-level technology center; in China, it has attained leading position for hepatic disease, diabetes, tuberculosis and clinical diagnosis products in segment market; in the global market, it has turned a front runner in the field of antimalarial drug, among others. Sinopharm Holdings contributed by Fosun Pharma has listed on Hong Kong Stock Exchange in 2009, which ranks leading position in China’s pharmaceutical distribution field on global market value. At present, Sinopharm has more than 10% of market share, its sales revenue has exceeded the sum total of the companies ranked No.2 and No. 3. In pharmaceutical retail field, Fosun Pharma’s subordinate enterprises, Guoda Pharmacy, For Me Pharmacy and Golden Elephant Pharmacy, holding the lead in brand and profitability in their regional markets, and forming pharmaceutical retail pattern via setting basis in Beijing and Shanghai as well as facing to national market.

Outstanding market performance has make Fosun Pharma become the case of global top business colleges; sustained and steady development has made it be a benchmark of China’s Listed Companies and hold a leading position in the industry; the brand of the company has enjoyed the trust in medical & health industry and capital market.

Fosun Pharma follows the principle of sustainable development and lays the same focus on the social responsibilities, economic and ecological benefits of the company. The responsibilities of corporate citizen have been a part of long term development strategy; Fosun Pharma is always dedicated to the public welfare establishments and the development of Guangcai Programme in China, as well as actively assists Chinese government in foreign aid as well as invests over 100 million RMB in education, salvation of the disabled and disaster relief.